A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma

Kazuya Takakuwa, Kaoru Mogushi, Min Han, Tomoaki Fujii, Masaki Hosoya, Arina Yamanami, Tomomi Akita, Chikamasa Yamashita, Tetsu Hayashida, Shunsuke Kato, Shigeo Yamaguchi

研究成果: Article

抜粋

Many driver pathways for cancer cell proliferation have been reported. Driver pathway activation is often evaluated based on a single hotspot mutation such as EGFR L858R. However, because of complex intratumoral networks, the impact of a driver pathway cannot be predicted based on only a single gene mutation. Here, we developed a novel diagnostic system named the “EGFR impact score” which is based on multiplex mRNA expression profiles, which can predict the impact of the EGFR pathway in lung cancer cells and the effect of EGFR-tyrosine kinase inhibitors on malignancy. The EGFR impact score indicated robust predictive power for the prognosis of early-stage lung cancer because this score can evaluate the impact of the EGFR pathway on the tumor and genomic instability. Additionally, the molecular features of the poor prognostic group resembled those of biomarkers associated with immune checkpoint inhibitors. The EGFR impact score is a novel prognostic and therapeutic indicator for lung adenocarcinoma.

元の言語English
記事番号6214
ジャーナルScientific reports
10
発行部数1
DOI
出版物ステータスPublished - 2020 12 1

ASJC Scopus subject areas

  • General

フィンガープリント A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Takakuwa, K., Mogushi, K., Han, M., Fujii, T., Hosoya, M., Yamanami, A., Akita, T., Yamashita, C., Hayashida, T., Kato, S., & Yamaguchi, S. (2020). A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma. Scientific reports, 10(1), [6214]. https://doi.org/10.1038/s41598-020-63200-7